The STELLAR trial: A phase II/III study of high-dose, intermittent sunitinib in patients with recurrent glioblastoma

DOI

These data support the main findings described in 'The STELLAR trial: A phase II/III study of high-dose, intermittent sunitinib in patients with recurrent glioblastoma.The data contains the results from the STELLAR trial, registered on ClinicalTrials.gov (NCT03025893). In total 55 patients were randomized 1:1 between treatment with high-dose intermittent sunitinib (either 300mg Q1W or 700mg Q2W) and lomustine. The trial was performed in three centers in the Netherlands (AmsterdamUMC, UMCG and Radboudumc).

Date Submitted: 2023-10-16

Identifier
DOI https://doi.org/10.17026/dans-x38-pz3s
Metadata Access https://lifesciences.datastations.nl/oai?verb=GetRecord&metadataPrefix=oai_datacite&identifier=doi:10.17026/dans-x38-pz3s
Provenance
Creator J.B.E. Janssen ORCID logo
Publisher DANS Data Station Life Sciences
Contributor Jorien Janssen; H.M.W. Verheul (Erasmus MC); M.E. Van Linde (AmsterdamUMC)
Publication Year 2024
Rights DANS Licence; info:eu-repo/semantics/closedAccess; https://doi.org/10.17026/fp39-0x58
OpenAccess false
Contact Jorien Janssen (RadboudUMC)
Representation
Resource Type Dataset
Format application/vnd.oasis.opendocument.spreadsheet; application/zip
Size 10907; 15809; 22387
Version 2.0
Discipline Life Sciences; Medicine